Automated and streamlined manufacturing of TIL therapies

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

The use of tumor-infiltrating T cells (TILs) for cancer therapy has shown some tremendous results, leading to the first FDA approval in early 2024. Yet, the journey towards clinical realization presents some important challenges that demand innovative solutions.

TIL manufacturing processes are complex and elaborate, with limitations caused by several open steps and the handling of multiple devices. These processes are time-consuming, prone to human error, and challenging to upscale. Streamlined manufacturing processes are thus key to ensure future success.

This webinar will highlight the potential of a novel TIL manufacturing process for streamlined and automated TIL manufacturing in a single device.

First, Dr Ian Hardy (Miltenyi Biotec) will introduce the features of the automated and closed manufacturing process and address how to efficiently manufacture TILs derived from different sources for clinical applications.

Next, Professor Lars Ny (University of Gothenburg) will provide early insights into the development of a locoregional cell therapy using TILS in patients with liver metastases of ocular melanoma.

• Discover the features of a novel TIL manufacturing process
• Learn how to harness closed system automation for manufacturing of TIL from different sources (tumor digest, yTILs)
• Gain insights into the development of locoregional cell therapy using TILS in patients with liver metastases of ocular melanoma

Ian Hardy

Director of T Cell Therapy for Personalized Immunotherapy at Miltenyi Biotec

Ian Hardy is a Director of T cell Therapy for Personalized Immunotherapy at Miltenyi Biotec, an innovative globally acting company that provides products and services that drive biomedical research and boost cell and gene therapy. Ian helped launch the CliniMACS TRT Prodigy Process and his group now works to help Miltenyi bring innovative T cell therapies from conceptualization to preclinical validation and clinical translation.

Lars Ny

Professor Immuno-Oncology, Deputy Head, Inst Kliniska Vetenskaper, Sahlgrenska Akademin at Göteborgs Universitet

Lars Ny is a professor of Immuno-Oncology at the University of Gothenburg and Senior Consultant in Oncology at Sahlgrenska University Hospital in Sweden. He is Head of the Melanoma Oncology Service and deputy director of the Institute of Clinical Sciences, Sahlgrenska Academy.

As a dual specialist in clinical pharmacology and oncology, Lars supervises graduate students and postdoctoral fellows and teaches at both undergraduate and postgraduate levels. His research focuses on cell therapy for metastatic melanoma. Lars has co-ordinated more than 20 clinical trials and published more than 100 peer-reviewed articles (h-index 40). He has been an editor for Acta Oncologica since 2022.